Potential for sarcopenia? Mitsubishi-funded trial shows NMN intake improves motor function in older men
A 12-week RCT funded by Mitsubishi Corporation Life Sciences has shown that nicotinamide mononucleotide (NMN) intake has significantly improved certain aspects of muscle mobility, especially gait speed and left grip strength – which the company says presents a 'potential therapeutic strategy for sarcopenia'.
